NeoRecormon gets CHMP OK for anemia
Switzerland-based drug major Roche says that the European Medicines Agency's (EMEA) Committee for Products for Human Use has recommended approval of NeoRecormon (epoetin-beta), as a subcutaneous 30,000 IU dose for the treatment of chemotherapy-induced anemia in patients with solid tumors.
Roche added that anemia affects up to 95% of patients receiving chemotherapy, which can often result in extreme fatigue that adds to the overall burden of illness. The firm also revealed that, in Europe, approximately 60% of cancer patients do not receive treatment for anemia.
The firm explained that the positive CHMP opinion is based on data from the BRAVE (BReast cancer Anemia and the Value of Erythropoietin) study, which was conducted in women with metastatic breast cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze